& Events
& Events
News
& Events
Apr 19, 2023 Inversago Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
MONTREAL (CANADA) – April 19, 2023 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, will present at the upcoming 2023 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 26, 2023 at 11:00 a.m. […]
Jan 24, 2023 Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference
MONTREAL (CANADA) – January 24, 2023 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that François Ravenelle, Ph.D., Chief Executive Officer, and Glenn Vraniak, MBA, Chief Financial Officer, will host investor meetings during the Private Company Exhibition at the 2023 SVB Securities […]
Nov 29, 2022 Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease
Data from Phase 2 Clinical Trial May Also Provide Insights into Diabetes- and Obesity-related Complications MONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 […]
Oct 19, 2022 Inversago Pharma Announces Appointment of Ed Mathers, BSc and Nanna Lüneborg, PhD, MBA to its Board of Directors
– Board appointments following recent $95 million CAD Series C Financing MONTREAL (CANADA) – October 19, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced the appointment of two new board members: Ed Mathers, BSc, General Partner at New Enterprise Associates (“NEA”) […]